Abstract: An expansion bridge chip for a modular chip system includes at least one upstream interface for communicating with an application processor module, a plurality of downstream interfaces for communicating with peripheral modules, and an upstream address decoder on each interface for directing data on the upstream interface to a downstream interface. In such an expansion bridge chip, each upstream interface may have a first bandwidth, each downstream interface may have a respective bandwidth, and the expansion bridge chip may be balanced, such that a sum of all respective bandwidths of the plurality of downstream interfaces is equal to the first bandwidth. Alternatively, each upstream interface may have a first bandwidth, each of the downstream interfaces may have a respective bandwidth, and the expansion bridge chip is unbalanced, such that a sum of all respective bandwidths of the plurality of downstream interfaces exceeds the first bandwidth, and interfaces contend for bandwidth.

Abstract: According to the present disclosure, there is an electrode for a lithium sulphur cell. The electrode comprises a matrix deposited on a current collector, wherein the matrix comprises an electrically conductive material, an electroactive sulphur material and a binder comprising a polymer that is crosslinked to form a crosslinked polymer network.

Abstract: A receiver receiving data includes: a first receiver configured to receive data in a first frequency band; a second receiver configured to receive second data in a second frequency band, the second frequency band being a subset of the first frequency band; and a data selector configured to select the frequency of operation of the second receiver from within the second frequency band in accordance with information representing the physical geographical location of the receiving device.

Abstract: The present invention is an inflatable balloon which is enclosed by an expandable cover which becomes increasingly porous/permeable during expansion. The balloon is coated or enclosed with a matrix which contains a pharmaceutically active agent. During expansion of the balloon, the pharmaceutically active agent is released or extruded through the expandable cover into a body cavity such as an artery or vein. The present invention also provides for a method of treating a disease or condition by delivering the inflatable balloon to a particular body cavity.

Abstract: The present invention relates to an anode for an electrochemical cell, said anode comprising a lithium metal or lithium metal alloy, and a polymer coating deposited on the lithium metal or lithium metal alloy, wherein the polymer coating is doped with lithium ions and comprises a polyisocyanurate material.

Abstract: The present invention is an inflatable balloon which is enclosed by an expandable cover which becomes increasingly porous/permeable during expansion. The balloon is coated or enclosed with a matrix which contains a pharmaceutically active agent. During expansion of the balloon, the pharmaceutically active agent is released or extruded through the expandable cover into a body cavity such as an artery or vein. The present invention also provides for a method of treating a disease or condition by delivering the inflatable balloon to a particular body cavity.

Abstract: Discharging pretreated biomass from a pretreatment reactor and mixing the discharged pretreated biomass with a cooling liquid in a vessel provides a cooled slurry having a consistency that is less than about 12 wt %. Since the consistency is relatively low, the cooled slurry may be pumped to a higher elevation using standard pumping equipment. At the higher elevation, the cooled slurry may be separated into a first stream comprising a liquid component of the slurry and a second other stream comprising a solid component of the slurry (e.g., having a consistency between about 15 wt % and 40 about wt %). The solid component may be fed to an inlet of a hydrolysis reactor, while the liquid component may be fed to a cooling system that provides a cooled stream. The cooled stream may then be cycled back to the vessel.

Abstract: The method includes the following steps: (i) feeding a slurry into the inlet of a press; (ii) removing liquid from the slurry as the slurry advances through a deliquefying section of the press, thereby producing a pressate stream; (iii) forming a plug of material as the slurry is advanced through a plug formation section of the press; (iv) advancing the plug of material to a discharge section of the press; and (v) removing additional liquid from the plug of material by operating the press so that the pressure in the discharge section of the press is greater than the pressure of the pressate stream by at least 2 psi. There is also described a method for controlling discharge consistency from a press, without provision of discharge restrictors, by varying a pressure differential between a discharge section of the press and a pressate stream.

Abstract: A process for the production of glucose from a pretreated lignocellulosic feedstock is provided. The method comprises enzymatically hydrolyzing the pretreated lignocellulosic feedstock with cellulase enzymes to produce a hydrolyzate slurry comprising glucose and unhydrolyzed cellulose and fermenting the hydrolyzate slurry in a fermentation reaction to produce a fermentation broth comprising alcohol. A process stream is obtained comprising unhydrolyzed cellulose, which is then subjected to a denaturing step, preferably comprising exposing the unhydrolyzed cellulose to elevated temperatures, thereby producing a heat-treated stream comprising the unhydrolyzed cellulose. The heat-treated stream comprising unhydrolyzed cellulose is then further hydrolyzed with cellulase enzymes to hydrolyze the cellulose to glucose.

Abstract: A method is provided for hydrolyzing polysaccharides in a lignocellulosic feedstock to produce monosaccharides or pretreating a lignocellulosic feedstock, in which an aqueous slurry of the lignocellulosic feedstock is fed into a pressurized dewatering zone wherein the feedstock is partially dewatered and then is compressed into a plug. The plug is introduced into a reaction zone that operates at a pressure (Pr) equal to greater than about 90 psia and under suitable temperature and pH conditions to hydrolyze the polysaccharides or pretreat the feedstock. The plug provides a pressure seal between the outlet of the dewatering zone and the reaction zone. The pressure (Pdwi) of the aqueous slurry of the lignocellulosic feedstock at the inlet of the dewatering device is related to Pr as follows: 0??P<the lesser of [(Pr?20 psia) and 220 psia], and where ?P is the absolute difference in pressure between Pr and Pdwi in psia.

Abstract: A pressure-energized, annular metallic seal is provided that includes a central annular portion and a pair of annular leg portions extending from the central portion. Each leg portion includes a convex sealing surface lying in sealing plane. One of the leg portions preferably has an annular flange offset from its sealing plane in an axial direction towards the sealing plane of the other leg portion. One of the leg portions preferably has at least one radially extending tab projecting further than adjacent parts of the seal. The seal is preferably manufactured by first cutting a first annular edge in a metallic sheet material, then bending the sheet material substantially into the shape of the seal, and then cutting a second annular edge to complete the shape of the seal. The second annular edge preferably defines the annular flange and/or the at least one tab.

Abstract: A method is provided for hydrolyzing polysaccharides in a lignocellulosic feedstock to produce monosaccharides or pretreating a lignocellulosic feedstock, in which an aqueous slurry of the lignocellulosic feedstock is fed into a pressurized dewatering zone wherein the feedstock is partially dewatered and then is compressed into a plug. The plug is introduced into a reaction zone that operates at a pressure (Pr) equal to greater than about 90 psia and under suitable temperature and pH conditions to hydrolyze the polysaccharides or pretreat the feedstock. The plug provides a pressure seal between the outlet of the dewatering zone and the reaction zone. The pressure (Pdwi) of the aqueous slurry of the lignocellulosic feedstock at the inlet of the dewatering device is related to Pr as follows: 0??P<the lesser of [(Pr?20 psia) and 220 psia], and where ?P is the absolute difference in pressure between Pr and Pdwi in psia.

Abstract: A process for the production of glucose from a pretreated lignocellulosic feedstock is provided. The method comprises enzymatically hydrolyzing the pretreated lignocellulosic feedstock with cellulase enzymes to produce a hydrolyzate slurry comprising glucose and unhydrolyzed cellulose and fermenting the hydrolyzate slurry in a fermentation reaction to produce a fermentation broth comprising alcohol. A process stream is obtained comprising unhydrolyzed cellulose, which is then subjected to a denaturing step, preferably comprising exposing the unhydrolyzed cellulose to elevated temperatures, thereby producing a heat-treated stream comprising the unhydrolyzed cellulose. The heat-treated stream comprising unhydrolyzed cellulose is then further hydrolyzed with cellulase enzymes to hydrolyze the cellulose to glucose.

Abstract: Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

Abstract: Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate adherence, growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to prevent intimal hyperplasia. Methods for preparing such medical devices, compositions, and methods for treating a mammal with vascular disease such as restenosis, artherosclerosis or other types of vessel obstructions are disclosed.

Abstract: Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells.

Abstract: This invention provides compositions and methods for producing a medical device coated with a matrix and an antibody which reacts with an endothelial cell antigen. The matrix coating the medical device may be composed of synthetic material, such as polyurethane, poly-L-lactic acid, cellulose ester or polyethylene glycol. In another embodiment, the matrix is composed of naturally occurring materials, such as collagen, fibrin, elastin, amorphous carbon. In a third embodiment, the matrix may be composed of fillerenes. The fullerenes range from about C60 to about C100. The medical device may be a stent or a synthetic graft. The antibodies promote adherence of eadothelial cells on the medical device. The antibodies may be mixed with the matrix or covalently tethered through a linker molecule to the matrix. Following adherence to the medical device, the endothelial cells differentiate and proliferate on the medical device. The antibodies may be different types of monoclonal antibodies.

Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

Abstract: A drug eluting medical device is provided for implanting into vessels or luminal structures within the body of a patient. The coated medical device, such as a stent, vascular, or synthetic graft comprises a coating consisting of a controlled-release matrix of a bioabsorbable, biocompatible, bioerodible, biodegradable, nontoxic material, such as a Poly(DL-Lactide-co-Glycolide) polymer, and at least one pharmaceutical substance, or bioactive agent incorporated within the matrix or layered within layers of matrix. In particular, the drug eluting medical device when implanted into a patient, delivers the drugs or bioactive agents within the matrix to adjacent tissues in a controlled and desired rate depending on the drug and site of implantation.

Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.